patmedfarПациентоориентированная медицина и фармацияPatient-Oriented Medicine and Pharmacy2949-1924LLC Izdatelstvo OKI10.37489/2949-1924-0043HMBQMRpatmedfar-70Research ArticleНЕВРОЛОГИЯNEUROLOGYЛабораторные маркеры депрессии: обзор литературыLaboratory markers of depression: literature reviewhttps://orcid.org/0009-0009-8059-9511ОвчинниковС. О.OvchinnikovS. O.

Овчинников Семен Олегович — студент лечебного факультета, специальность «медицинская биохимия»

Ярославль

Semyon O. Ovchinnikov — student of the Faculty of Medicine, specialty "medical biochemistry"; anesthesiologist-resuscitator

Yaroslavl

Semik312@inbox.ruhttps://orcid.org/0000-0002-4769-4113КасаткинД. С.KasatkinD. S.

Касаткин Дмитрий Сергеевич — д. м. н., профессор кафедры нервных болезней с медицинской генетикой и нейрохирургией

Ярославль

Dmitry S. Kasatkin — MD, PhD, Professor, Chair of Nervous Diseases with Medical Genetics and Neurosurgery

Yaroslavl

dskasatkin@gmail.comФГБО ВО «Ярославский государственный медицинский университет» Министерства здравоохранения Российской ФедерацииРоссияYaroslavl State Medical UniversityRussian Federation202428032024216166Copyright © Овчинников С.О., Касаткин Д.С., 20242024Овчинников С.О., Касаткин Д.С.Ovchinnikov S.O., Kasatkin D.S.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.pomph.ru/jour/article/view/70

Поиск лабораторных маркеров депрессии в настоящее время является потенциальным ключом к пониманию механизмов развития заболевания, персонифицированному подбору антидепрессантной терапии и, что наиболее важно, определению чётких, специфических, объективных диагностических критериев. Потребность в установлении биомаркеров депрессивного расстройства открывает широкое поле для исследований многих регуляторных систем организма. Выявленные на данный момент лабораторные маркеры участвуют в нейротрофических, нейроэндокринных, нейромедиаторных, метаболических и воспалительных процессах. В обзоре рассмотрены особенности использования различных биомаркеров для изучения депрессии с целью представления самых перспективных из них.

The search for laboratory markers of depression is currently a potential key to understanding the mechanisms of disease development, selecting personalized antidepressant therapy, and defining clear, specific, and objective diagnostic criteria. Identifying biomarkers of depressive disorder offers a broad field for researching many regulatory systems of the body. The laboratory markers identified so far are involved in neurotrophic, neuroendocrine, neurotransmitter, metabolic, and inflammatory processes. This review discusses the use of various biomarkers for studying depression, focusing on the most promising ones.

депрессивное расстройстводепрессиялабораторные маркерыбиомаркерыdepressive disorderdepressionlaboratory markersbiomarkersReferencesKapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry. 2012 Dec;17(12):1174-9. doi: 10.1038/mp.2012.105.Kapur S, Phillips AG, Insel TR. Why has it taken so long for biological psychiatry to develop clinical tests and what to do about it? Mol Psychiatry. 2012 Dec;17(12):1174-9. doi: 10.1038/mp.2012.105.Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008 Jan 3;358(1):55-68. doi: 10.1056/NEJMra073096.Belmaker RH, Agam G. Major depressive disorder. N Engl J Med. 2008 Jan 3;358(1):55-68. doi: 10.1056/NEJMra073096.Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2163-96. doi: 10.1016/S0140-6736(12)61729-2. Erratum in: Lancet. 2013 Feb 23;381(9867):628.Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2012 Dec 15;380(9859):2163-96. doi: 10.1016/S0140-6736(12)61729-2. Erratum in: Lancet. 2013 Feb 23;381(9867):628.Lehto SM, Huotari A, Niskanen L, Tolmunen T, Koivumaa-Honkanen H, Honkalampi K, Ruotsalainen H, Herzig KH, Viinamäki H, Hintikka J. Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatr Scand. 2010 Mar;121(3):209-15. doi: 10.1111/j.1600-0447.2009.01463.x.Lehto SM, Huotari A, Niskanen L, Tolmunen T, Koivumaa-Honkanen H, Honkalampi K, Ruotsalainen H, Herzig KH, Viinamäki H, Hintikka J. Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatr Scand. 2010 Mar;121(3):209-15. doi: 10.1111/j.1600-0447.2009.01463.x.Tichomirowa MA, Keck ME, Schneider HJ, Paez-Pereda M, Renner U, Holsboer F, Stalla GK. Endocrine disturbances in depression. J Endocrinol Invest. 2005 Jan;28(1):89-99. doi: 10.1007/BF03345535.Tichomirowa MA, Keck ME, Schneider HJ, Paez-Pereda M, Renner U, Holsboer F, Stalla GK. Endocrine disturbances in depression. J Endocrinol Invest. 2005 Jan;28(1):89-99. doi: 10.1007/BF03345535.Lehto SM, Huotari A, Niskanen L, Tolmunen T, Koivumaa-Honkanen H, Honkalampi K, Ruotsalainen H, Herzig KH, Viinamäki H, Hintikka J. Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatr Scand. 2010 Mar;121(3):209-15. doi: 10.1111/j.1600-0447.2009.01463.x.Lehto SM, Huotari A, Niskanen L, Tolmunen T, Koivumaa-Honkanen H, Honkalampi K, Ruotsalainen H, Herzig KH, Viinamäki H, Hintikka J. Serum adiponectin and resistin levels in major depressive disorder. Acta Psychiatr Scand. 2010 Mar;121(3):209-15. doi: 10.1111/j.1600-0447.2009.01463.x.Małujło-Balcerska E, Pietras T. Adipocytokines levels as potential biomarkers for discriminating patients with a diagnosis of depressive disorder from healthy controls. J Psychiatr Res. 2024 Mar;171:163-170. doi: 10.1016/j.jpsychires.2024.01.026.Małujło-Balcerska E, Pietras T. Adipocytokines levels as potential biomarkers for discriminating patients with a diagnosis of depressive disorder from healthy controls. J Psychiatr Res. 2024 Mar;171:163-170. doi: 10.1016/j.jpsychires.2024.01.026.Kirkegaard C, Faber J. The role of thyroid hormones in depression. Eur J Endocrinol. 1998 Jan;138(1): 1-9. doi: 10.1530/eje.0.1380001.Kirkegaard C, Faber J. The role of thyroid hormones in depression. Eur J Endocrinol. 1998 Jan;138(1): 1-9. doi: 10.1530/eje.0.1380001.Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, Nierenberg AA, Fava M, Wong KK. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol. 2008 Mar;18(3):230-3. doi: 10.1016/j.euroneuro.2007.06.004.Simon NM, McNamara K, Chow CW, Maser RS, Papakostas GI, Pollack MH, Nierenberg AA, Fava M, Wong KK. A detailed examination of cytokine abnormalities in Major Depressive Disorder. Eur Neuropsychopharmacol. 2008 Mar;18(3):230-3. doi: 10.1016/j.euroneuro.2007.06.004.Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008 Sep 15;64(6):527-32. doi: 10.1016/j.biopsych.2008.05.005.Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008 Sep 15;64(6):527-32. doi: 10.1016/j.biopsych.2008.05.005.Fontanari AM, Andreazza T, Costa ÂB, et al. Serum concentrations of brain-derived neurotrophic factor in patients with gender identity disorder. Journal of Psychiatric Research. 2013 Oct;47(10):1546-1548. DOI: 10.1016/j.jpsychires.2013.04.012.Fontanari AM, Andreazza T, Costa ÂB, et al. Serum concentrations of brain-derived neurotrophic factor in patients with gender identity disorder. Journal of Psychiatric Research. 2013 Oct;47(10):1546-1548. DOI: 10.1016/j.jpsychires.2013.04.012.Li YJ, Xu M, Gao ZH, Wang YQ, Yue Z, Zhang YX, Li XX, Zhang C, Xie SY, Wang PY. Alterations of serum levels of BDNF-related miRNAs in patients with depression. PLoS One. 2013 May 21;8(5):e63648. doi: 10.1371/journal.pone.0063648.Li YJ, Xu M, Gao ZH, Wang YQ, Yue Z, Zhang YX, Li XX, Zhang C, Xie SY, Wang PY. Alterations of serum levels of BDNF-related miRNAs in patients with depression. PLoS One. 2013 May 21;8(5):e63648. doi: 10.1371/journal.pone.0063648.Liu Y, Yang X, Zhao L, Zhang J, Li T, Ma X. Increased miR-132 level is associated with visual memory dysfunction in patients with depression. Neuropsychiatr Dis Treat. 2016 Nov 9;12:2905-2911. doi: 10.2147/NDT.S116287.Liu Y, Yang X, Zhao L, Zhang J, Li T, Ma X. Increased miR-132 level is associated with visual memory dysfunction in patients with depression. Neuropsychiatr Dis Treat. 2016 Nov 9;12:2905-2911. doi: 10.2147/NDT.S116287.Su M, Hong J, Zhao Y, Liu S, Xue X. MeCP2 controls hippocampal brain-derived neurotrophic factor expression via homeostatic interactions with microR-NA-132 in rats with depression. Mol Med Rep. 2015 Oct;12(4):5399-406. doi: 10.3892/mmr.2015.4104.Su M, Hong J, Zhao Y, Liu S, Xue X. MeCP2 controls hippocampal brain-derived neurotrophic factor expression via homeostatic interactions with microR-NA-132 in rats with depression. Mol Med Rep. 2015 Oct;12(4):5399-406. doi: 10.3892/mmr.2015.4104.Lopez JP, Fiori LM, Cruceanu C, Lin R, Labonte B, Cates HM, Heller EA, Vialou V, Ku SM, Gerald C, Han MH, Foster J, Frey BN, Soares CN, Müller DJ, Farzan F, Leri F, MacQueen GM, Feilotter H, Tyryshkin K, Evans KR, Giacobbe P, Blier P, Lam RW, Milev R, Parikh SV, Rotzinger S, Strother SC, Lewis CM, Aitchison KJ, Wittenberg GM, Mechawar N, Nestler EJ, Uher R, Kennedy SH, Turecki G. MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. Nat Commun. 2017 May 22;8:15497. doi: 10.1038/ncomms15497.Lopez JP, Fiori LM, Cruceanu C, Lin R, Labonte B, Cates HM, Heller EA, Vialou V, Ku SM, Gerald C, Han MH, Foster J, Frey BN, Soares CN, Müller DJ, Farzan F, Leri F, MacQueen GM, Feilotter H, Tyryshkin K, Evans KR, Giacobbe P, Blier P, Lam RW, Milev R, Parikh SV, Rotzinger S, Strother SC, Lewis CM, Aitchison KJ, Wittenberg GM, Mechawar N, Nestler EJ, Uher R, Kennedy SH, Turecki G. MicroRNAs 146a/b-5 and 425-3p and 24-3p are markers of antidepressant response and regulate MAPK/Wnt-system genes. Nat Commun. 2017 May 22;8:15497. doi: 10.1038/ncomms15497.Spijker S, Van Zanten JS, De Jong S, Penninx BW, van Dyck R, Zitman FG, Smit JH, Ylstra B, Smit AB, Hoogendijk WJ. Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol Psychiatry. 2010 Jul 15;68(2):179-86. doi: 10.1016/j.biopsych.2010.03.017.Spijker S, Van Zanten JS, De Jong S, Penninx BW, van Dyck R, Zitman FG, Smit JH, Ylstra B, Smit AB, Hoogendijk WJ. Stimulated gene expression profiles as a blood marker of major depressive disorder. Biol Psychiatry. 2010 Jul 15;68(2):179-86. doi: 10.1016/j.biopsych.2010.03.017.Huang S, Li Y, Shen J, Liang W, Li C. Identification of a diagnostic model and molecular subtypes of major depressive disorder based on endoplasmic reticulum stress-related genes. Front Psychiatry. 2023 Aug 15;14:1168516. doi: 10.3389/fpsyt.2023.1168516.Huang S, Li Y, Shen J, Liang W, Li C. Identification of a diagnostic model and molecular subtypes of major depressive disorder based on endoplasmic reticulum stress-related genes. Front Psychiatry. 2023 Aug 15;14:1168516. doi: 10.3389/fpsyt.2023.1168516.Woo HI, Lim SW, Myung W, Kim DK, Lee SY. Differentially expressed genes related to major depressive disorder and antidepressant response: genome-wide gene expression analysis. Exp Mol Med. 2018 Aug 3;50(8):1-11. doi: 10.1038/s12276-018-0123-0.Woo HI, Lim SW, Myung W, Kim DK, Lee SY. Differentially expressed genes related to major depressive disorder and antidepressant response: genome-wide gene expression analysis. Exp Mol Med. 2018 Aug 3;50(8):1-11. doi: 10.1038/s12276-018-0123-0.Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008 Sep 15;64(6):527-32. doi: 10.1016/j.biopsych.2008.05.005.Sen S, Duman R, Sanacora G. Serum brain-derived neurotrophic factor, depression, and antidepressant medications: meta-analyses and implications. Biol Psychiatry. 2008 Sep 15;64(6):527-32. doi: 10.1016/j.biopsych.2008.05.005.Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006 Jun 15;59(12):1116-27. doi: 10.1016/j.bio-psych.2006.02.013.Duman RS, Monteggia LM. A neurotrophic model for stress-related mood disorders. Biol Psychiatry. 2006 Jun 15;59(12):1116-27. doi: 10.1016/j.bio-psych.2006.02.013.Thakker-Varia S, Alder J. Neuropeptides in depression: role of VGF. Behav Brain Res. 2009 Feb 11;197(2):262-78. doi: 10.1016/j.bbr.2008.10.006.Thakker-Varia S, Alder J. Neuropeptides in depression: role of VGF. Behav Brain Res. 2009 Feb 11;197(2):262-78. doi: 10.1016/j.bbr.2008.10.006.Thakker-Varia S, Krol JJ, Nettleton J, Bilimoria PM, Bangasser DA, Shors TJ, Black IB, Alder J. The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. J Neurosci. 2007 Nov 7;27(45):12156-67. doi: 10.1523/JNEUROS-CI.1898-07.2007.Thakker-Varia S, Krol JJ, Nettleton J, Bilimoria PM, Bangasser DA, Shors TJ, Black IB, Alder J. The neuropeptide VGF produces antidepressant-like behavioral effects and enhances proliferation in the hippocampus. J Neurosci. 2007 Nov 7;27(45):12156-67. doi: 10.1523/JNEUROS-CI.1898-07.2007.Hage MP, Azar ST. The Link between Thyroid Function and Depression. J Thyroid Res. 2012;2012:590648. doi: 10.1155/2012/590648.Hage MP, Azar ST. The Link between Thyroid Function and Depression. J Thyroid Res. 2012;2012:590648. doi: 10.1155/2012/590648.Sullivan GM, Mann JJ, Oquendo MA, Lo ES, Cooper TB, Gorman JM. Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Biol Psychiatry. 2006 Sep 1;60(5):500-6. doi: 10.1016/j.biopsych.2005.11.022.Sullivan GM, Mann JJ, Oquendo MA, Lo ES, Cooper TB, Gorman JM. Low cerebrospinal fluid transthyretin levels in depression: correlations with suicidal ideation and low serotonin function. Biol Psychiatry. 2006 Sep 1;60(5):500-6. doi: 10.1016/j.biopsych.2005.11.022.Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N, Rahmoune H, Bahn S. Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function. Eur Arch Psychiatry Clin Neurosci. 2012 Dec;262(8):657-66. doi: 10.1007/s00406-012-0301-3.Martins-de-Souza D, Guest PC, Vanattou-Saifoudine N, Rahmoune H, Bahn S. Phosphoproteomic differences in major depressive disorder postmortem brains indicate effects on synaptic function. Eur Arch Psychiatry Clin Neurosci. 2012 Dec;262(8):657-66. doi: 10.1007/s00406-012-0301-3.Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci. 2012;8(9):1254-66. doi: 10.7150/ijbs.4679.Erta M, Quintana A, Hidalgo J. Interleukin-6, a major cytokine in the central nervous system. Int J Biol Sci. 2012;8(9):1254-66. doi: 10.7150/ijbs.4679.Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008 Oct 16;455(7215):894-902. doi: 10.1038/nature07455.Krishnan V, Nestler EJ. The molecular neurobiology of depression. Nature. 2008 Oct 16;455(7215):894-902. doi: 10.1038/nature07455.Deuschle M, Sander P, Herpfer I, Fiebich BL, Heuser I, Lieb K. Substance P in serum and cerebrospinal fluid of depressed patients: no effect of antidepressant treatment. Psychiatry Res. 2005 Jul 15;136(1): 1-6. doi: 10.1016/j.psychres.2004.12.007.Deuschle M, Sander P, Herpfer I, Fiebich BL, Heuser I, Lieb K. Substance P in serum and cerebrospinal fluid of depressed patients: no effect of antidepressant treatment. Psychiatry Res. 2005 Jul 15;136(1): 1-6. doi: 10.1016/j.psychres.2004.12.007.Carpenter LL, Bayat L, Moreno F, Kling MA, Price LH, Tyrka AR, Kinkead B, Owens MJ, Nemeroff CB. Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Psychiatry Res. 2008 Jan 15;157 (1-3):123-9. doi: 10.1016/j.psychres.2007.04.016.Carpenter LL, Bayat L, Moreno F, Kling MA, Price LH, Tyrka AR, Kinkead B, Owens MJ, Nemeroff CB. Decreased cerebrospinal fluid concentrations of substance P in treatment-resistant depression and lack of alteration after acute adjunct vagus nerve stimulation therapy. Psychiatry Res. 2008 Jan 15;157 (1-3):123-9. doi: 10.1016/j.psychres.2007.04.016.Alacreu-Crespo A, Olié E, Guillaume S, Girod C, Cazals A, Chaudieu I, Courtet P. Dexamethasone Suppression Test May Predict More Severe/ Violent Suicidal Behavior. Front Psychiatry. 2020 Mar 4;11:97. doi: 10.3389/fpsyt.2020.00097.Alacreu-Crespo A, Olié E, Guillaume S, Girod C, Cazals A, Chaudieu I, Courtet P. Dexamethasone Suppression Test May Predict More Severe/ Violent Suicidal Behavior. Front Psychiatry. 2020 Mar 4;11:97. doi: 10.3389/fpsyt.2020.00097.Fountoulakis KN, Gonda X, Rihmer Z, Fokas C, Iacovides A. Revisiting the Dexamethasone Suppression Test in unipolar major depression: an exploratory study. Ann Gen Psychiatry. 2008 Nov 13;7:22. doi: 10.1186/1744-859X-7-22.Fountoulakis KN, Gonda X, Rihmer Z, Fokas C, Iacovides A. Revisiting the Dexamethasone Suppression Test in unipolar major depression: an exploratory study. Ann Gen Psychiatry. 2008 Nov 13;7:22. doi: 10.1186/1744-859X-7-22.Jani BD, McLean G, Nicholl BI, Barry SJ, Sattar N, Mair FS, Cavanagh J. Risk assessment and predicting outcomes in patients with depressive symptoms: a review of potential role of peripheral blood based biomarkers. Front Hum Neurosci. 2015 Feb 2;9:18. doi: 10.3389/fnhum.2015.00018.Jani BD, McLean G, Nicholl BI, Barry SJ, Sattar N, Mair FS, Cavanagh J. Risk assessment and predicting outcomes in patients with depressive symptoms: a review of potential role of peripheral blood based biomarkers. Front Hum Neurosci. 2015 Feb 2;9:18. doi: 10.3389/fnhum.2015.00018.

The authors declare that there are no conflicts of interest present.